Conduit Pharmaceuticals Inc. (CDTTW)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Conduit Pharmaceuticals Inc. (CDTTW) is up 172.7% since the beginning of the year. At $0 per share, CDTTW is trading 30.9% below its 52-week high of $0.

Conduit Pharmaceuticals Inc. (CDTTW) has returned 172.73% so far this year and 40.19% over the past 12 months.

Based on dividend-adjusted daily data since Sep 25, 2023, CDTTW's average daily return is +2.10%, while the average monthly return is +11.24%. At this rate, an investment would double in approximately 0.5 years.

Historically, 50% of months were positive and 50% were negative. The best month was Nov 2023 with a return of +266.7%, while the worst month was Dec 2024 at -70.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.

On a daily basis, CDTTW closed higher 29% of trading days. The best single day was Nov 29, 2023 with a return of +421.3%, while the worst single day was Apr 24, 2024 at -59.0%.

Conduit Pharmaceuticals Inc. has an annualized alpha of 14984.60%, beta of 1.06, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 26, 2023.

• This stock participated in 424.43% of S&P 500 Index downside but only 302.61% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CDTTW ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Conduit Pharmaceuticals Inc. (CDTTW) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Conduit Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Conduit Pharmaceuticals Inc. was 96.07%, occurring on Dec 31, 2025. The portfolio has not yet recovered.

The current Conduit Pharmaceuticals Inc. drawdown is 89.28%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Conduit Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Conduit Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.